Abiopharma

🔍 Gottschalk Alexandra (Executive)

Company: Perella Weinberg Partners (PWP)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 4,000 shares of Class A Common Stock (Direct)
  Date: 2026-08-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 76,492.00 | transaction_form_type: 4
• Sold 1,626 shares of Class A Common Stock at $16.98 per share (Direct)
  Date: 2026-08-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 74,866.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,000 shares of Performance-Based Stock Units (Derivative)
  Date: 2026-08-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Represents deemed disposition of shares of Class A common stock to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• F2: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of Class A common stock.
• F3: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of Class A common stock. PSUs vest based on the achievement of (i) service-based vesting conditions that are satisfied in five equal installments on the 36, 42, 48, 54 and 60 month anniversaries of the grant date and (ii) performance-based vesting conditions that are satisfied upon the achievement of closing stock price hurdles for 20 out of any 30 consecutive trading days equal to $12, $13.50, $15 and $17, in each case prior to the sixth anniversary of the grant date.
• F4: These PSUs vested on August 31, 2026, upon the achievement of certain service-based and performance-based vesting conditions.